Closing the gap: the EUROASPIRE study (European Action on Secondary Prevention by Intervention to Reduce Events) and what it can tell us for the treatment of diabetes patients.
Newly emerging data from the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial: an investigator’s perspective.